Don't miss key details from the Mueller report. Sign up for Axios AM.


Cancer drug company criticized for price hikes hires lobbyist

The Capitol Building in Washington D.C. is lit up at night.
Tri-Source Pharma hired a firm to lobby on "drug pricing law." Photo: Bill Clark/CQ Roll Call via Getty Images

Tri-Source Pharma has hired its first lobbying firm, Mercury Strategies, to influence federal "drug pricing law and regulation," according to a lobbying disclosure from this month. Tri-Source is the parent of NextSource Biotechnology, a firm that was heavily criticized after the Wall Street Journal reported it has hiked the price of its off-patent cancer pill by 1,400% since 2013.

The bottom line: President Trump's drug plan won't really change how drug companies set their list prices, but those firms still want a seat at the table. Tri-Source, which filed lawsuits against critics earlier this year, and Mercury Strategies did not answer multiple phone calls.